|
1
|
Broad neutralization coverage of HIV by multiple highly potent antibodies.
|
Nature
|
2011
|
11.07
|
|
2
|
A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield.
|
Science
|
2011
|
5.44
|
|
3
|
Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans.
|
PLoS Pathog
|
2013
|
2.66
|
|
4
|
The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies.
|
PLoS Pathog
|
2013
|
1.67
|
|
5
|
Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque.
|
Proc Natl Acad Sci U S A
|
2011
|
1.61
|
|
6
|
PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4.
|
J Virol
|
2012
|
1.58
|
|
7
|
Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching.
|
J Virol
|
2004
|
1.50
|
|
8
|
Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors.
|
Proc Natl Acad Sci U S A
|
2004
|
1.46
|
|
9
|
A gp41 MPER-specific llama VHH requires a hydrophobic CDR3 for neutralization but not for antigen recognition.
|
PLoS Pathog
|
2013
|
0.97
|
|
10
|
Conserved changes in envelope function during human immunodeficiency virus type 1 coreceptor switching.
|
J Virol
|
2007
|
0.93
|
|
11
|
Evolution of CXCR4-using human immunodeficiency virus type 1 SF162 is associated with two unique envelope mutations.
|
J Virol
|
2007
|
0.86
|
|
12
|
One-year routine opportunistic screening for hypertension in formal medical settings and potential improvements in hypertension awareness among older persons in developing countries: evidence from the Study on Global Ageing and Adult Health (SAGE).
|
Am J Epidemiol
|
2014
|
0.77
|